"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Descriptor ID |
D018358
|
MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 1 | 0 | 1 |
1997 | 2 | 0 | 2 |
1998 | 2 | 1 | 3 |
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 5 | 0 | 5 |
2005 | 2 | 2 | 4 |
2006 | 6 | 1 | 7 |
2007 | 8 | 0 | 8 |
2008 | 8 | 1 | 9 |
2009 | 5 | 0 | 5 |
2010 | 11 | 1 | 12 |
2011 | 20 | 1 | 21 |
2012 | 14 | 4 | 18 |
2013 | 10 | 1 | 11 |
2014 | 22 | 1 | 23 |
2015 | 16 | 1 | 17 |
2016 | 20 | 1 | 21 |
2017 | 20 | 0 | 20 |
2018 | 11 | 1 | 12 |
2019 | 18 | 0 | 18 |
2020 | 18 | 3 | 21 |
2021 | 21 | 1 | 22 |
2022 | 19 | 0 | 19 |
2023 | 10 | 0 | 10 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Apr 01; 31(4).
-
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024 02 16; 30(4):680-686.
-
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet J Rare Dis. 2024 Feb 16; 19(1):73.
-
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16; 25(1):58.
-
Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2023 Nov 17; 108(12):3260-3271.
-
A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in 177 Lu-DOTATATE therapy. Med Phys. 2023 Nov; 50(11):7222-7235.
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010.
-
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 09 04; 33(9):1359-1369.
-
Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat. 2023 Nov; 202(1):23-32.
-
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023 08 01; 30(8).